Key statistics dashboard for Caribou Biosciences, Inc. (CRBU). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally.
Stock Data
| Price | $1.25 |
| Market Cap | $124M |
| Beta | 2.46 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -1.18 |
| Price / Book | 1.31 |
| P/S | 12.55 |
| P/FCF | -1.32 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | -129.70% |
| EBIT Margin | -1056.97% |
| EBITDA Margin | -1037.42% |
| Operating Margin | -1090.90% |
| Net Margin | -1030.42% |
Financial Health
| Current Ratio | 6.49 |
| Quick Ratio | 6.49 |
| Cash Ratio | 1.46 |
| Debt / Equity | 0.27 |
| Debt / Assets | 18.67% |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 0.10 |
| Book Value per share | 0.97 |
| Cash per share | 1.11 |
| FCF per share | -0.95 |
| Tangible Book Value per share | 0.97 |
| Dividend per share | 0.00 |
Related companies: AARD · ALLO · ENTA · FHTX · HUMA · IVA · OBIO
Explore sector: Healthcare · Biotechnology
More sections of CRBU: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks